Does rapamycin extend lifespan in humans?

Short answer: we don't know yet, and no study has directly tested it. What's well established is that rapamycin extends lifespan in mice (animal evidence). In humans, the evidence so far covers biomarkers and short-term safety, not actual lifespan – a human lifespan trial would take decades. The strongest human evidence to date is a systematic review of human data reporting improvements in immune, cardiovascular, and skin parameters, not a mortality outcome.

The evidence, by study type

Evidence	What it means	Studies
S	Synthesis of human data	1
H	Human study	16
A	Animal model	32
M	Molecular — cells, biochemistry, structure	24
R	Review — secondary literature, not a new result	4
PP	Preprint, not peer-reviewed	1
RT	Registered trial, no results yet	1

Rapamycin is the most-studied intervention in this Atlas for its effect on the mTOR pathway (79 studies total).

What each kind of study actually shows

• LEE2024 S – the first systematic review of rapamycin/rapalogs in humans specifically for aging; found improvements in immune, cardiovascular, and skin parameters – biomarkers and safety, not a lifespan endpoint.
• MOE2025 H – a 48-week randomized controlled trial (n=114) found NO significant change in its primary endpoint, visceral fat by DXA (p=0.942) – a null result worth knowing about, since not every human trial confirms the mouse findings.
• KRA2018 H – low-dose rapamycin was tolerable in older adults over 8+ weeks, with only minor adverse events.
• HAR2009 A – rapamycin fed starting at 600 days of age (late-middle-age for a mouse) extended both median and maximal lifespan in both sexes (age at 90% mortality rose 14% in females and 9% in males).
• BIT2016 A – just 3 months of rapamycin late in life increased subsequent life expectancy by up to 60% – the lifespan benefit doesn't require lifelong dosing. The 60% figure comes from males on the high injected dose. At that dose females gained no survival benefit and developed more aggressive blood cancers; the lower dietary dose raised survival in both sexes, so dose and route matter as much as the pulse.
• SAR2006 M – long-term dosing also suppresses mTORC2 signaling in many cell types – the likely mechanism behind the insulin resistance seen with daily dosing.

The honest gap

Nobody has run – or can easily run – a randomized trial that follows healthy humans on rapamycin for the decades it would take to measure an actual lifespan effect. Every human data point so far is a proxy: biomarkers, short-term safety, or one physiological outcome like visceral fat. Whether mTORC1-selective (mTORC2-sparing) dosing could capture the mouse-study longevity signal without the human metabolic downside is one of the Atlas's 10 open questions, each paired with a proposed experiment. See the full open question.

Related entities

Open in the Atlas explorer